Business
Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research
-- Research Veteran Brings More than 30 Years of Industry and NIH Experience to Kite Leadership Team -- SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a
About this update from Gilead Sciences, Inc.
[{"type":"text","content":"\n-- Research Veteran Brings More than 30 Years of Industry and NIH Experience to Kite Leadership Team --\n\n SANTA MONICA, Calif.--(BUSINESS WIRE)--\nKite, a Gilead Company (Nasdaq: GILD), today announced that Francesco Marincola, MD, will join the company as Senior Vice President and Global Head of Cell Therapy Research, effective February 1. Dr. Marincola will lead Kite’s Research organization across hematological malignancies and solid tumors.\n\n“Franco’s proven track record in oncology and robust research experience that spans the NIH to industry will be critical to the targeting and acceleration of our research efforts in CAR T and beyond,” said Christi Shaw, Chief Executive Officer of Kite. “As the cell therapy leader, we are thrilled to welcome Franco to our team and are confident that his exceptional skills and expertise will best position our research to discover potentially life-saving therapies for patients in need.”\n\nDr. Marincola joins Kite from Refuge Biotechnologies Inc., where he was President and Chief Scientific Officer, responsible for the development and implementation of research and clinical development of synthetic biology strategies for adoptive cell therapy products and lead therapeutic programs based on nuclease deactivated CRISPR circuits. He is also a National Institutes of Health (NIH) tenured senior investigator in cancer immunotherapy and biomarker research, and spent 23 years at the NIH, including 15 years as the Chief of the Infectious Disease and Immunogenetics Section at the NIH Clinical Center. Previously, he also served as a distinguished research fellow in immune oncology discovery at AbbVie and as Chief Research Officer at Sidra Research in Doha, Qatar. The former President of the Society for Immunotherapy of Cancer (SITC; 2013-2014), he currently serves as Editor-in-Chief for several prominent peer-reviewed publications, including Journal of Translational Medicine, Translational Medicine Communications and Immunotherapy, and is the author of more than 600 peer-reviewed publications.\n\n“It is an honor to bring my experience to an industry-leading team that is working to make cell therapies with curative intent available to patients,” said Dr. Marincola. “I look forward to helping build and diversify our research efforts in support of this mission.”\n\nAbout Kite\n\nKite, a Gilead Compa...